


# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY DOCKET NO.  
1000.06.

SERIAL NO.  
10/082,521

TUMOR CHEMOPOTENTIATION

FILING

02/22/02

GROUP

1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>[Signature]</i>	A1	6,020,363	02/01/00	HIRANO, ET AL	5M	15	

RECEIVED  
JUL 25 2002  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>[Signature]</i>	C1	Teicher et al., "Optimal Scheduling of Interleukin-12 and Fractionated Radiation Therapy in the Murine Lewis Lung Carcinoma," Radiation Oncology Investigations, 6:71-80, 1998.
<i>[Signature]</i>	C2	Kawai et al., "Enhancement of Anticancer Effects of Radiation and Conventional Anticancer Agents by a Quinolinone derivative, Vesnarinone: Studies on Human Gastric Cancer Tissues in Nude Mice, Anticancer Res., 18:405-412, 1998.


EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

1000.06.

Application Number

09/794,417

Applicant(s)

TUMOR RADIOSENSITIZATION ...

Filing Date

02/27/01

Group Art Unit

1614

\*EXAMINER

INITIAL

OTHER DOCUMENTS (Including Abstract, Title, Date, Pertinent Pages, Etc.)

Voest et al., "Inhibition of Angiogenesis In Vivo by Interleukin 12," J. Nat'l Cancer Inst., 87:581-586, 1995.

C3

Gorski et al., "Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation, Cancer Res., 59:3374-3378, 1999.

C4

Norioka et al., "Interaction of Interleukin-1 and Interferon-g on Fibroblast Growth Factor-Induced Angiogenesis, Jpn. J. cancer Res., 85:522-529, 1994.

C5

Mauceri et al., "Combined effects of Angiostatin and Ionizing Radiation in Antitumor Therapy," Nature, 394:287-291, 1998.

C6

Matsumoto et al. "Synthesis and Biological Evaluation of Cytogenin Derivatives," J. Antibiotics, 54:285-296, 2001.

C7

Salloum et al., "NM-3, an Isocoumarin, Increases the Antitumor Effect of radiotherapy without Toxicity, Cancer Res., 60:6958-6963, 2000.

C8

Agata et al., "NM-3, a Novel Angiogenesis Inhibitor, Potentiates Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells, Proceedings of the 2001 AACR-NCI-EORTC International Conference, p67 October 2001.

C9

Yin et al., "The Novel Isocoumarin 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl) Propionic Acid (NM-3) Induces lethality of Human Carcinoma Cells by Generation of Reactive Oxygen Species," Mol. cancer Therapeutics, 1:43-48, 2001.

C10

Reimer et al., "Antineoplastic Effects of Chemotherapeutic Agents are Potentiated by NM-3, an Inhibitor of Angiogenesis," Cancer Res., 62:789-795, 2002.

C11

Nakashima, et al., "Inhibition of Angiogenesis by a New Isocoumarin NM-3," J. Antibiotics, 52:426-428, 1999.

C12

Kumagi, et al., "Antitumor Activity of Cytogenin," J. Antibiotics, 48:175-178, 1995.

C13

Oikawa, et al., "Effects of Cytogenin, a Novel Microbial Product, on Embryonic and Tumor Cell-Induced Angiogenic Responses In Vivo," Anticancer Res., 17:1881-1886, 1997.

C14

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.